ABSTRACT
Resumen La infección por SARS-CoV2 es una pandemia. Se creía que el primer caso de esta enfermedad ocurrió el 8 de diciembre de 2019 en la provincia de Hubei en China, aunque posteriormente se indicó que el primer caso confirmado por laboratorio ocurrió el 1.( de diciembre de 2019 ante la presencia de un brote de neumonía en 59 pacientes sospechosos en un mercado local de mariscos en Wuhan. No solo produce patología respiratoria, con frecuencia compremete el sistema cardiovascular ya que produce lesión miocárdica, miocarditis, y, con cierta frecuencia, aumenta la descompensación de enfermedades cardiovasculares preestablecidas. En este artículo se trata de dilucidar el componente cardiovascular hasta ahora existente en la literatura y se sugieren algunos pasos a seguir en pacientes con estas enfermedades, acorde con la evidencia actual.
Abstract Infection due to SARS-CoV2 is a pandemic. It is believed that the first case occurred on 8 December 2019 in Hubei province in China, although it was later indicated that the first laboratory-confirmed case occurred on 1 December 2019 due to the presence of an outbreak of suspected pneumonia in 59 patients in a shellfish market in Wuhan. It not only caused a respiratory disease, it often compromised the cardiovascular system since it produces a myocardial lesion, myocarditis, and, less often, increased the decompensation of pre-established cardiovascular diseases. An attempt is made in this article to elucidate the cardiovascular component presented in the current literature, and to suggest some steps to follow in patients with these diseases in accordance with the current evidence.
Subject(s)
Humans , Male , Female , Coronavirus , Heart Failure , Pneumonia , Respiratory Distress Syndrome, Newborn , Myocardial Reperfusion Injury , Severe Acute Respiratory Syndrome , MyocarditisABSTRACT
Objective:To discuss the curative effect of phosphocreatine adjuvant treatment on neonatal hypoxic -ischemic myocardi-al lesion and its influence on serum IL-6 and myocardial enzyme .Methods:Totally 80 cases of newborns with hypoxic-ischemic myo-cardial lesion were divided into the observation group and the control group at random .The two groups were given the routine medical treatment, including maintenance of ventilation , warmth, water-electrolyte and acid-base balance, heart rate, blood pressure, nutrition support and etc, while the newborns in the control group were additionally given 250 mg· kg-1 1,6 diphosphate (FDP), ivgtt bid, for 10 days, while those in the observation group , were additionally given 1.0g phosphocreatine dissolved in 100 ml 0.9% normal saline (NS) on the basis of the treatment of the control group , ivgtt qd, for 10 days.The clinical curative effect and security were observed and the changes of serum IL-6 and myocardial enzyme in the two groups were compared .Results: The levels of LDH, CK, CK-MB and serum IL-6 in the two groups were obviously declined when compared with those before the treatment (P<0.05 or P<0.01), and the declining rate of the observation group was higher than that of the control group (P<0.05).The total clinical efficiency of the ob-servation group was higher than that in the control group after the medical treatment (P<0.05), and no serious untoward effect ap-peared in the two groups during the medical treatment .Conclusion: Phosphocreatine has significant curative effect on neonatal hy-poxic-ischemic myocardial lesion , which can effectively improve myocardial function of newborns and reduce myocardial enzyme and se -rum IL-6 levels.